Office safety presentations

Common Questions and Answers about Office safety presentations

safety

Avatar m tn These presentations will disclose updated clinical, pre-clinical and mechanistic data on the activity of NAPs against chronic hepatitis B and hepatitis D infection: ยท Updated clinical data from the ongoing REP 301 study assessing the safety and efficacy of REP 2139-Ca combined with pegylated interferon in patients with hepatitis B / hepatitis D co-infection (poster FRI-105).
Avatar m tn Following a brief introduction by Margaret Hamburg, Commissioner of the Food and Drug Administration, the briefing will provide an overview of the clinical trials, primary efficacy, safety, and complexity of dosing regimens. The briefing will consist of presentations by Debra Birnkrant, M.D, Director, and Jeffery Murray, Deputy Director, Division of Antiviral Products, Center for Drug Evaluation and Research (CDER), followed by an opportunity for questions from call participants.
572651 tn?1530999357 //www.aan.com/globals/axon/assets/9324.pdf Even if I don't understand all the details, the concepts of what they are studying is always fascinating to review. The poster presentation listing starts on page 49.
Avatar m tn , Commissioner of the Food and Drug Administration, the briefing will provide an overview of the clinical trials, primary efficacy, safety, and complexity of dosing regimens. The briefing will consist of presentations by Debra Birnkrant, M.D, Director, and Jeffery Murray, Deputy Director, Division of Antiviral Products, Center for Drug Evaluation and Research (CDER), followed by an opportunity for questions from call participants.
Avatar m tn Recently the International Workshop on Anti-viral Drug Resistance was held in Berlin, Germany. The section on HBV concentrated on future therapies. These presentations are very technical, I would appreciate comments from studyforhope. http://www.informedhorizons.com/resistance2014/presentations.html Personally I have two specific questions: 1. China is conducting a Phase 2 clinical trial on GLS4, a nucleocapsid inihibitor based on Bayer 41-4109 (HAP).
Avatar m tn I don't think I've seen this yet here.... http://www.vrtx.com/easl2011.
Avatar m tn REEF-1 (NCT03982186) is a Phase 2b, multicenter, double-blind, active-controlled, randomized study to assess the efficacy and safety over 48 weeks of monthly subcutaneous injections of JNJ-3989 (3 dose levels of 40, 100, and 200mg) and/or 250mg daily oral JNJ-6379 in combination with daily oral NA in currently not treated or virally suppressed patients with HBeAg positive or negative CHB. Patients were required to have HBsAg levels greater than 100 IU/mL to enter the study.
Avatar f tn The involuntary side effect is called tardive dyskinesia, and there are a variety of presentations. The literature says once it develops it does not go away, however the literature is wrong. If it is a side effect and the medicines are discontinued, the syndrome often disappears.
Avatar f tn CMX157 was shown to be 60-fold more active than tenofovir against the hepatitis B virus, or HBV, based on in vitro studies. This significant potency difference has considerable potential in increasing the safety profile and reducing the side effects compared to tenofovir DF, or Gilead's (GILD) Viread. The company believes CMX157's lipid-conjugate design clearly differentiates it from tenofovir DF.
572651 tn?1530999357 If you want to see what the neruologists and other medical folks discussed in Lyon, France, this week at ECTRIMS, (European Committee for Treatment and Research in MS), they have posted the videos/web clips of over 30 presentations at the conference. This is your chance to learn the latest news from the MS research and doctor world - each one is probably about 45-60 minutes, so you will need lots of popcorn.
Avatar m tn So I'm in my second year of biology right now and I learned a few days ago that a class I'll be taking involves lot's of group work and presentations. The problem is that I have a severe social anxiety disorder and really cannot do presentations at all. Group work is okay, when I'm interacting with just a few people it's not too hard. In high school all my presentations were done just in front of the teacher and no one else.
Avatar m tn me again! if you go up a directory to page: http://www.ezpresenter.net/msa/swf Then there is a list of several presentations. They are named by presented, not topic so I'm not sure what they are all about but I think they are all MS related. Thanks again!
Avatar n tn I have been a pediatric dental assistant for over 8 years. we sedate 3-4 patients a day in our office(between 3 doctors). We use two medications to sedate our little ones. Chloral Hydrate and Vistaril is what we use. Age 1 to 10 years old. These medications are concious sedation meds. They have a very high index of safety because it is done based on a range of weights. Making it hard to over sed. Unless you just don't go by the guidelines.
572651 tn?1530999357 the FDA issued a formal safety alert today about the dangers of CCSVI treatment. You can read the details at: http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm303318.
Avatar f tn In Australia there is a site called kidsafe that rates all available car seats, prams, strollers, cots etc that are available. It rates everything from safety through to prices. Just wondering if perhaps the US has a similar site!